Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 13/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | KDM4A | O75164 | 1/20 | 0.38 |
| ▸ | KDM5C | P41229 | 1/20 | 0.38 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.38 |
| ▸ | LATS1 | O95835 | 4/20 | 0.36 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.32 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17891438 | 0.82 | KDM4C (0.44) | KDM4CLATS1 | |
| SCHEMBL17615552 | 0.81 | LATS1 (0.47) | KDM4CKDM4ELATS1CSNK2A2CSNK2B | |
| SCHEMBL20239677 | 0.81 | LATS1 (0.47) | KDM4CLATS1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL17602303 | 0.79 | KDM4C (0.40) | KDM4CLATS1LATS2 | |
| SCHEMBL20801271 | 0.78 | CSNK2A1 (0.44) | KDM4CLATS1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL17623576 | 0.77 | LATS1 (0.39) | KDM4CKDM4EKDM4AKDM5CKDM4D | |
| SCHEMBL17615556 | 0.76 | LATS1 (0.49) | KDM4CLATS1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL30139676 | 0.74 | KDM4C (0.64) | KDM4CKDM4EKDM4AKDM5CKDM4D | |
| SCHEMBL17602068 | 0.74 | KDM4C (0.64) | KDM4CKDM4EKDM4AKDM5CKDM4D | |
| SCHEMBL17503810 | 0.73 | SMN1; SMN2 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9643965-B2 | Histone demethylase inhibitors | Celgene Quantical Research, Inc. (US) | 2017-05-09 | — | — | US | disclosed |
| US-20160083379-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083379-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5C | KDM4C 9/4885KDM4E 17/4885KDM4A 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.